Thank you for the solid and considered posts ..I have the...

Thank you for the solid and considered posts ..

I have the fortunate position of being a Biotech Investor for just over 25 years .

Currently I could not give you another example of a Company carrying ot CR's at such a frequency at ever diminishing values.
Especially coupled to "Complete Response" Announcements in fact Multiple Complete Response Announcements.

I only have 2 questions for the BOD

1, First why wasn't the SP allowed to run on the last announcement?

2, What warrants a 50% discount on a "Complete Response Announcement"?
surely that would warrant a Premium but at the very least an on Par CR to the SP..

I believe due to the frequency of CR's at ever diminishing values will warrant some questions to be answered by ASIC and the ASX.

From the IPO Investments are down circa 99% to the current SP,, large Salaries have been paid to Manage a 99% decline in Investor Value.
The Company breached the 2 x Quarter Operating Capital Regulation so demonstrates extremely poor cash management abilities.

If CHM did go to the wall, then you can be sure questions will be asked ,,'How did the Company with the closest Cure to Cancer collapse"? and I can assure you its not the fault of SH.... NZT

We have no choice but to ride this one either into Oblivion or over the rainbow to a pot of gold... but those that paid 35c will require a 70 bagger to break even... 20c a 40 bagger..... 5c is a Disallowed a 1000% increase...

Great Science ,, just the timeline was extended , staff paid far to much and Funds managed into suspension... NZT